Clinical Trials
159 trialsNCT01351896 2026-05-27
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07605416 2026-05-26
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT01446133 2026-05-22
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02334865 2026-05-15
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT02160015 2026-05-13
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04301076 2026-05-13
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05283720 2026-05-06
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT04542824 2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04623541 2026-05-05
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT00843882 2026-05-01
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01522976 2026-04-30
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01723839 2026-04-03
FCR
Hackensack Meridian Health
Phase 2 Completed
NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT05870917 2026-03-02
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT02312102 2026-01-16
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
NCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT02005289 2025-12-15
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06517017 2025-11-28
UltraFrailMM
University of Utah
Phase 2 Recruiting
NCT02568553 2025-11-26
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01995669 2025-06-24
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01729091 2025-05-09
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00848328 2025-04-24
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Terminated
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT05828459 2025-03-20
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
Phase 1 Recruiting
NCT06762431 2025-01-07
VTB-CLL002
Vitebsk Regional Clinical Cancer Centre
Phase 1/2 Enrolling by invitation
NCT01919619 2024-12-03
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01199575 2024-08-15
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Phase 2 Completed
NCT06547944 2024-08-09
ZGR in TN CLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Active not recruiting
NCT02843074 2023-12-05
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT01772420 2023-07-27
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Albert Einstein College of Medicine
Phase 2 Completed
NCT01754857 2023-06-27
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
University of Wisconsin, Madison
Phase 2 Completed
NCT02280525 2023-06-07
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00602459 2023-05-22
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00783367 2023-03-30
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02225275 2022-09-28
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01886859 2022-09-26
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT03379051 2022-08-22
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
TG Therapeutics, Inc.
Phase 1/2 Terminated
NCT01241786 2022-07-20
VZCLLPI0146
Hackensack Meridian Health
Phase 2 Terminated
NCT01744912 2022-05-11
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
TG Therapeutics, Inc.
Phase 1 Terminated
NCT04490707 2022-03-24
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
Zhongda Hospital
Phase 3 Unknown
NCT01433965 2022-03-10
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
University of California, Davis
Phase 1 Completed
NCT00352365 2022-02-11
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01578954 2022-01-27
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01125176 2022-01-21
ThRiL
Weill Medical College of Cornell University
Phase 2 Completed
NCT01556776 2022-01-05
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
German CLL Study Group
Phase 3 Completed
NCT00774345 2021-12-02
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
Celgene
Phase 3 Completed
NCT00792077 2021-07-01
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
M.D. Anderson Cancer Center
Phase 2 Completed